Considering that GBM patients that lack MGMT promoter methylation derive minimal therapeutic benefit from temozolomide treatment57, PRMT5 inhibition instead of temozolomide, in combination with established surgical and radiotherapy protocols, may improve outcomes for this cohort of patients. This evidence concerns the gene PRMT5 and glioblastoma.